Details of Xenobiotics-DME Interaction (XEOTIC)

General Information of Drug-Metabolizing Enzyme (DME ID: DME0091)
DME Name Prostaglandin G/H synthase 1 (COX-1), Homo sapiens DME Info
UniProt ID
PGH1_HUMAN
EC Number    EC: 1.14.99.1     (Click to Show/Hide the Complete EC Tree)
Oxidoreductase
Oxygen paired donor oxidoreductase
Oxygen paired donor oxidoreductase
EC: 1.14.99.1
Lineage    Species: Homo sapiens     (Click to Show/Hide the Complete Species Lineage)
Kingdom: Metazoa
Phylum: Chordata
Class: Mammalia
Order: Primates
Family: Hominidae
Genus: Homo
Species: Homo sapiens
Interactome
Interactions between Xenobiotics and DME (XEOTIC)
      Fungicide(s), Herbicide(s) or Insecticide(s)
                  Herbicide Click to Show/Hide the Full List of Xenobiotics:        1 Xenobiotics
                              Atrazine Click to Show/Hide the Detail Induction
                                 XEOTIC ID XEO00969   XEOTIC Info Gene Form mRNA
                                 Classification Herbicide
                                 DME Modulation Atrazine up-regulates the expression of DME PTGS1 [1]
      Health or Environmental Toxicant(s)
                  Acute Toxic Substance Click to Show/Hide the Full List of Xenobiotics:        1 Xenobiotics
                              Enniatins Click to Show/Hide the Detail Inhibition
                                 XEOTIC ID XEO01289   XEOTIC Info Gene Form mRNA
                                 Classification Acute Toxic Substance
                                 DME Modulation Enniatins inhibits the expression of DME PTGS1 [2]
                  Carcinogen Click to Show/Hide the Full List of Xenobiotics:        1 Xenobiotics
                              Sodium bichromate Click to Show/Hide the Detail Inhibition
                                 XEOTIC ID XEO01024   XEOTIC Info Gene Form mRNA
                                 Classification Carcinogen
                                 DME Modulation Sodium bichromate inhibits the expression of DME PTGS1 [3]
                  Health Hazard/Toxicant Click to Show/Hide the Full List of Xenobiotics:        2 Xenobiotics
                              Acetaldehyde Click to Show/Hide the Detail Induction
                                 XEOTIC ID XEO00872   XEOTIC Info Gene Form mRNA
                                 Classification Health Hazard
                                 DME Modulation Acetaldehyde up-regulates the expression of DME PTGS1 [4]
                              Diethylhexyl phthalate Click to Show/Hide the Detail Inhibition
                                 XEOTIC ID XEO01004   XEOTIC Info Gene Form mRNA
                                 Classification Health Hazard
                                 DME Modulation Diethylhexyl phthalate inhibits the expression of DME PTGS1 [5]
      Natural Product(s), Extract(s) or Medicine(s)
                  Natural Mixture Click to Show/Hide the Full List of Xenobiotics:        1 Xenobiotics
                              Amphibole asbestos Click to Show/Hide the Detail Inhibition
                                 XEOTIC ID XEO00995   XEOTIC Info Gene Form Protein
                                 Classification Natural Mixture
                                 DME Modulation Amphibole asbestos inhibits the drug-metabolizing activity of DME PTGS1 [6]
                  Natural Product Click to Show/Hide the Full List of Xenobiotics:        3 Xenobiotics
                              4-oxoretinoic acid Click to Show/Hide the Detail Inhibition
                                 XEOTIC ID XEO01154   XEOTIC Info Gene Form mRNA
                                 Classification Natural Product
                                 DME Modulation 4-oxoretinoic acid inhibits the expression of DME PTGS1 [7]
                              Arzanol Click to Show/Hide the Detail Inhibition
                                 XEOTIC ID XEO01207   XEOTIC Info Gene Form Protein
                                 Classification Natural Product
                                 DME Modulation Arzanol inhibits the drug-metabolizing activity of DME PTGS1 [8]
                              Platelet activating factor Click to Show/Hide the Detail Induction
                                 XEOTIC ID XEO01434   XEOTIC Info Gene Form mRNA
                                 Classification Natural Product
                                 DME Modulation Platelet activating factor up-regulates the expression of DME PTGS1 [9]
      Pharmaceutical Agent(s)
                  Approved/Marketed Drug Click to Show/Hide the Full List of Xenobiotics:      29 Xenobiotics
                              Acetaminophen Click to Show/Hide the Detail Inhibition
                                 XEOTIC ID XEO00217   XEOTIC Info Gene Form Protein
                                 Classification Drug Approved by US FDA
                                 DME Modulation Acetaminophen inhibits the drug-metabolizing activity of DME PTGS1 in Spodoptera frugiperda (Sf9) cell (IC50 = 200 microM) [10]
                              Alitretinoin Click to Show/Hide the Detail Inhibition
                                 XEOTIC ID XEO00167   XEOTIC Info Gene Form mRNA
                                 Classification Drug Approved by US FDA
                                 DME Modulation Alitretinoin inhibits the expression of DME PTGS1 [7]
                              Arsenic trioxide Click to Show/Hide the Detail Inhibition
                                 XEOTIC ID XEO00339   XEOTIC Info Gene Form mRNA
                                 Classification Drug Approved by US FDA
                                 DME Modulation Arsenic trioxide inhibits the expression of DME PTGS1 [11]
                              Aspirin Click to Show/Hide the Detail Inhibition
                                 XEOTIC ID XEO00213   XEOTIC Info Gene Form Protein
                                 Classification Drug Approved by US FDA
                                 DME Modulation Aspirin inhibits the drug-metabolizing activity of DME PTGS1 (IC50 = 100 microM) [12]
                              Bupivacaine Click to Show/Hide the Detail Induction
                                 XEOTIC ID XEO00342   XEOTIC Info Gene Form mRNA
                                 Classification Drug Approved by US FDA
                                 DME Modulation Bupivacaine up-regulates the expression of DME PTGS1 [13]
                              Calcitriol Click to Show/Hide the Detail Induction
                                 XEOTIC ID XEO00184   XEOTIC Info Gene Form mRNA
                                 Classification Drug Approved by US FDA
                                 DME Modulation Calcitriol up-regulates the expression of DME PTGS1 [14], [15]
                              Celecoxib Click to Show/Hide the Detail Inhibition
                                 XEOTIC ID XEO00013   XEOTIC Info Gene Form Protein
                                 Classification Drug Approved by US FDA
                                 DME Modulation Celecoxib inhibits the drug-metabolizing activity of DME PTGS1 (IC50 < 100 microM) [16]
                              Cisplatin Click to Show/Hide the Detail Induction
                                 XEOTIC ID XEO00334   XEOTIC Info Gene Form mRNA
                                 Classification Drug Approved by US FDA
                                 DME Modulation Cisplatin up-regulates the expression of DME PTGS1 [17]
                              Dexamethasone Click to Show/Hide the Detail Induction
                                 XEOTIC ID XEO00088   XEOTIC Info Gene Form mRNA
                                 Classification Drug Approved by US FDA
                                 DME Modulation Dexamethasone up-regulates the expression of DME PTGS1 [18]
                              Diclofenac Click to Show/Hide the Detail Inhibition
                                 XEOTIC ID XEO00352   XEOTIC Info Gene Form Protein
                                 Classification Drug Approved by US FDA
                                 DME Modulation Diclof DMEenac inhibits the drug-metabolizing activity of DME PTGS1 (IC50 = 0.003 microM) [19]
                              Dimethyl sulfoxide Click to Show/Hide the Detail Inhibition
                                 XEOTIC ID XEO00001   XEOTIC Info Gene Form mRNA
                                 Classification Drug Approved by US FDA
                                 DME Modulation Dimethyl sulfoxide inhibits the expression of DME PTGS1 [20]
                              Donepezil hydrochloride Click to Show/Hide the Detail Inhibition
                                 XEOTIC ID XEO00289   XEOTIC Info Gene Form mRNA
                                 Classification Drug Approved by US FDA
                                 DME Modulation Donepezil hydrochloride inhibits the expression of DME PTGS1 [21]
                              Doxorubicin hydrochloride Click to Show/Hide the Detail Inhibition
                                 XEOTIC ID XEO00292   XEOTIC Info Gene Form mRNA
                                 Classification Drug Approved by US FDA
                                 DME Modulation Doxorubicin hydrochloride inhibits the expression of DME PTGS1 [22]
                              Ethinyl estradiol Click to Show/Hide the Detail Inhibition
                                 XEOTIC ID XEO00267   XEOTIC Info Gene Form mRNA
                                 Classification Drug Approved by US FDA
                                 DME Modulation Ethinyl estradiol inhibits the expression of DME PTGS1 [23]
                              Etodolac Click to Show/Hide the Detail Inhibition
                                 XEOTIC ID XEO00034   XEOTIC Info Gene Form Protein
                                 Classification Drug Approved by US FDA
                                 DME Modulation Etodolac inhibits the drug-metabolizing activity of DME PTGS1 (IC50 = 10.3 microM) [24]
                              Flurbiprofen sodium Click to Show/Hide the Detail Inhibition
                                 XEOTIC ID XEO00296   XEOTIC Info Gene Form Protein
                                 Classification Drug Approved by US FDA
                                 DME Modulation Flurbiprof DMEen sodium inhibits the drug-metabolizing activity of DME PTGS1 (IC50 = 0.01 microM) [25]
                              Gemcitabine Click to Show/Hide the Detail Inhibition
                                 XEOTIC ID XEO00361   XEOTIC Info Gene Form mRNA
                                 Classification Drug Approved by US FDA
                                 DME Modulation Gemcitabine inhibits the expression of DME PTGS1 [26]
                              Ibuprofen Click to Show/Hide the Detail Inhibition
                                 XEOTIC ID XEO00248   XEOTIC Info Gene Form Protein
                                 Classification Drug Approved by US FDA
                                 DME Modulation Ibuprof DMEen inhibits the drug-metabolizing activity of DME PTGS1 in Human erythroleukemia cell line (HEL) (IC50 = 0.09865 microM) [27]
                              Indomethacin Click to Show/Hide the Detail Inhibition
                                 XEOTIC ID XEO00047   XEOTIC Info Gene Form Protein
                                 Classification Drug Approved by US FDA
                                 DME Modulation Indomethacin inhibits the drug-metabolizing activity of DME PTGS1 in U937 cell lines (IC50 = 0.002 microM) [28]
                              Isotretinoin Click to Show/Hide the Detail Inhibition
                                 XEOTIC ID XEO00186   XEOTIC Info Gene Form mRNA
                                 Classification Drug Approved by US FDA
                                 DME Modulation Isotretinoin inhibits the expression of DME PTGS1 [7]
                              Ketorolac tromethamine Click to Show/Hide the Detail Inhibition
                                 XEOTIC ID XEO00303   XEOTIC Info Gene Form Protein
                                 Classification Drug Approved by US FDA
                                 DME Modulation Ketorolac tromethamine inhibits the drug-metabolizing activity of DME PTGS1 in Platelet (IC50 = 0.013 microM) [29]
                              Naproxen Click to Show/Hide the Detail Inhibition
                                 XEOTIC ID XEO00156   XEOTIC Info Gene Form Protein
                                 Classification Drug Approved by US FDA
                                 DME Modulation Naproxen inhibits the drug-metabolizing activity of DME PTGS1 in Platelet (IC50 = 0.211 microM) [30]
                              Panobinostat Click to Show/Hide the Detail Inhibition
                                 XEOTIC ID XEO00372   XEOTIC Info Gene Form mRNA
                                 Classification Drug Approved by US FDA
                                 DME Modulation Panobinostat inhibits the expression of DME PTGS1 [31]
                              Progesterone Click to Show/Hide the Detail Induction
                                 XEOTIC ID XEO00094   XEOTIC Info Gene Form mRNA
                                 Classification Drug Approved by US FDA
                                 DME Modulation Progesterone up-regulates the expression of DME PTGS1 [32]
                              Rofecoxib Click to Show/Hide the Detail Inhibition
                                 XEOTIC ID XEO00078   XEOTIC Info Gene Form Protein
                                 Classification Drug Approved by US FDA
                                 DME Modulation Rof DMEecoxib inhibits the drug-metabolizing activity of DME PTGS1 (IC50 = 1.7 microM) [33], [34]
                              Tretinoin Click to Show/Hide the Detail Inhibition
                                 XEOTIC ID XEO00253   XEOTIC Info Gene Form mRNA
                                 Classification Drug Approved by US FDA
                                 DME Modulation Tretinoin inhibits the expression of DME PTGS1 [35]
                              Valproic acid Click to Show/Hide the Detail Induction
                                 XEOTIC ID XEO00029   XEOTIC Info Gene Form Protein
                                 Classification Drug Approved by US FDA
                                 DME Modulation Valproic acid up-regulates the expression of DME PTGS1 and leads to increasing the drug-metabolizing activity of this enzyme [36]
                              Lornoxicam Click to Show/Hide the Detail Inhibition
                                 XEOTIC ID XEO00503   XEOTIC Info Gene Form Protein
                                 Classification Drug Marketed but not Approved by US FDA
                                 DME Modulation Lornoxicam inhibits the drug-metabolizing activity of DME PTGS1 [37]
                              Thiostrepton Click to Show/Hide the Detail Induction
                                 XEOTIC ID XEO01485   XEOTIC Info Gene Form Protein
                                 Classification Drug Marketed but not Approved by US FDA
                                 DME Modulation Thiostrepton induces the drug-metabolizing activity of DME PTGS1 [38]
                  Drug in Phase 3 Clinical Trial Click to Show/Hide the Full List of Xenobiotics:        3 Xenobiotics
                              Curcumin Click to Show/Hide the Detail Inhibition
                                 XEOTIC ID XEO00683   XEOTIC Info Gene Form mRNA
                                 Classification Highest Clinical Status: Phase 3
                                 DME Modulation Curcumin inhibits the expression of DME PTGS1 [39]
                              Epigallocatechin gallate Click to Show/Hide the Detail Inhibition
                                 XEOTIC ID XEO00613   XEOTIC Info Gene Form mRNA
                                 Classification Highest Clinical Status: Phase 3
                                 DME Modulation Epigallocatechin gallate inhibits the expression of DME PTGS1 [39]
                              Resveratrol Click to Show/Hide the Detail Inhibition
                                 XEOTIC ID XEO00568   XEOTIC Info Gene Form Protein
                                 Classification Highest Clinical Status: Phase 3
                                 DME Modulation Resveratrol inhibits the drug-metabolizing activity of DME PTGS1 in Platelet (IC50 = 0.625 microM) [40], [41]
                  Drug in Phase 2 Clinical Trial Click to Show/Hide the Full List of Xenobiotics:        7 Xenobiotics
                              Butyric acid Click to Show/Hide the Detail Induction
                                 XEOTIC ID XEO01230   XEOTIC Info Gene Form mRNA
                                 Classification Highest Clinical Status: Phase 2/3
                                 DME Modulation Butyric acid up-regulates the expression of DME PTGS1 [42]
                              Antipyrine Click to Show/Hide the Detail Inhibition
                                 XEOTIC ID XEO00875   XEOTIC Info Gene Form Protein
                                 Classification Highest Clinical Status: Phase 2
                                 DME Modulation Antipyrine inhibits the drug-metabolizing activity of DME PTGS1 [43]
                              Bisphenol A Click to Show/Hide the Detail Inhibition
                                 XEOTIC ID XEO01226   XEOTIC Info Gene Form mRNA
                                 Classification Highest Clinical Status: Phase 2
                                 DME Modulation Bisphenol A inhibits the expression of DME PTGS1 [44]
                              CHF-5074 Click to Show/Hide the Detail Inhibition
                                 XEOTIC ID XEO00670   XEOTIC Info Gene Form Protein
                                 Classification Highest Clinical Status: Phase 2
                                 DME Modulation CHF-5074 inhibits the drug-metabolizing activity of DME PTGS1 [45]
                              Genistein Click to Show/Hide the Detail Inhibition
                                 XEOTIC ID XEO00557   XEOTIC Info Gene Form Protein
                                 Classification Highest Clinical Status: Phase 2
                                 DME Modulation Genistein inhibits the drug-metabolizing activity of DME PTGS1 (IC50 = 80 microM) [46]
                              MS-275 Click to Show/Hide the Detail Induction
                                 XEOTIC ID XEO00581   XEOTIC Info Gene Form mRNA
                                 Classification Highest Clinical Status: Phase 2
                                 DME Modulation MS-275 up-regulates the expression of DME PTGS1 [47]
                              Sulindac sulfide Click to Show/Hide the Detail Inhibition
                                 XEOTIC ID XEO00656   XEOTIC Info Gene Form Protein
                                 Classification Highest Clinical Status: Phase 2
                                 DME Modulation Sulindac sulfide inhibits the drug-metabolizing activity of DME PTGS1 (IC50 = 0.115 microM) [48]
                  Drug in Phase 1 Clinical Trial Click to Show/Hide the Full List of Xenobiotics:        4 Xenobiotics
                              Geldanamycin Click to Show/Hide the Detail Inhibition
                                 XEOTIC ID XEO00649   XEOTIC Info Gene Form mRNA
                                 Classification Highest Clinical Status: Phase 1
                                 DME Modulation Geldanamycin inhibits the expression of DME PTGS1 [11]
                              NS-398 Click to Show/Hide the Detail Inhibition
                                 XEOTIC ID XEO00583   XEOTIC Info Gene Form Protein
                                 Classification Highest Clinical Status: Phase 1
                                 DME Modulation NS-398 inhibits the drug-metabolizing activity of DME PTGS1 (IC50 = 220 microM) [49]
                              Quercetin Click to Show/Hide the Detail Inhibition
                                 XEOTIC ID XEO00538   XEOTIC Info Gene Form Protein
                                 Classification Highest Clinical Status: Phase 1
                                 DME Modulation Quercetin inhibits the drug-metabolizing activity of DME PTGS1 [50]
                              SC-58125 Click to Show/Hide the Detail Inhibition
                                 XEOTIC ID XEO00623   XEOTIC Info Gene Form Protein
                                 Classification Highest Clinical Status: Phase 1
                                 DME Modulation SC-58125 inhibits the drug-metabolizing activity of DME PTGS1 (IC50 = 32 microM) [51]
                  Preclinical/Patented Drug Click to Show/Hide the Full List of Xenobiotics:        5 Xenobiotics
                              Flosulide Click to Show/Hide the Detail Inhibition
                                 XEOTIC ID XEO00703   XEOTIC Info Gene Form Protein
                                 Classification Drug in Preclinical Study
                                 DME Modulation Flosulide inhibits the drug-metabolizing activity of DME PTGS1 in U937 cell lines (IC50 > 50 microM) [52]
                              Isoliquiritigenin Click to Show/Hide the Detail Inhibition
                                 XEOTIC ID XEO00710   XEOTIC Info Gene Form Protein
                                 Classification Drug in Preclinical Study
                                 DME Modulation Isoliquiritigenin inhibits the drug-metabolizing activity of DME PTGS1 (IC50 = 130 microM) [53]
                              Tripterine Click to Show/Hide the Detail Induction
                                 XEOTIC ID XEO00706   XEOTIC Info Gene Form mRNA
                                 Classification Drug in Preclinical Study
                                 DME Modulation Tripterine up-regulates the expression of DME PTGS1 [47]
                              Ferulic acid Click to Show/Hide the Detail Inhibition
                                 XEOTIC ID XEO00730   XEOTIC Info Gene Form mRNA
                                 Classification Patented Pharmaceutical Agent
                                 DME Modulation Ferulic acid inhibits the expression of DME PTGS1 [39]
                              SC-560 Click to Show/Hide the Detail Inhibition
                                 XEOTIC ID XEO01468   XEOTIC Info Gene Form Protein
                                 Classification Patented Pharmaceutical Agent
                                 DME Modulation SC-560 inhibits the drug-metabolizing activity of DME PTGS1 (IC50 = 0.007 microM) [54]
                  Drug Marketed but Withdrawn from Market Click to Show/Hide the Full List of Xenobiotics:        4 Xenobiotics
                              Dipyrone Click to Show/Hide the Detail Inhibition
                                 XEOTIC ID XEO00517   XEOTIC Info Gene Form Protein
                                 Classification Drug Marketed but Withdrawn from Market
                                 DME Modulation Dipyrone inhibits the drug-metabolizing activity of DME PTGS1 [43]
                              Flupenthixol Click to Show/Hide the Detail Inhibition
                                 XEOTIC ID XEO00528   XEOTIC Info Gene Form Protein
                                 Classification Drug Marketed but Withdrawn from Market
                                 DME Modulation Flupenthixol inhibits the drug-metabolizing activity of DME PTGS1 [55]
                              Nimesulide Click to Show/Hide the Detail Induction
                                 XEOTIC ID XEO00519   XEOTIC Info Gene Form mRNA
                                 Classification Drug Marketed but Withdrawn from Market
                                 DME Modulation Nimesulide up-regulates the expression of DME PTGS1 [56]
                              Phenacetin Click to Show/Hide the Detail Inhibition
                                 XEOTIC ID XEO00520   XEOTIC Info Gene Form mRNA
                                 Classification Drug Marketed but Withdrawn from Market
                                 DME Modulation Phenacetin inhibits the expression of DME PTGS1 [57]
                  Investigative Agent Click to Show/Hide the Full List of Xenobiotics:        2 Xenobiotics
                              Arachidonic acid Click to Show/Hide the Detail Induction
                                 XEOTIC ID XEO00876   XEOTIC Info Gene Form Protein
                                 Classification Investigative Agent
                                 DME Modulation Arachidonic acid induces the drug-metabolizing activity of DME PTGS1 [58], [59]
                              Cotylenin A Click to Show/Hide the Detail Induction
                                 XEOTIC ID XEO01260   XEOTIC Info Gene Form mRNA
                                 Classification Investigative Agent
                                 DME Modulation Cotylenin A up-regulates the expression of DME PTGS1 [15]
References
1 Endoplasmic reticulum stress impairs insulin signaling through mitochondrial damage in SH-SY5Y cells. Neurosignals. 2012;20(4):265-80.
2 Enniatin B induces expression changes in the electron transport chain pathway related genes in lymphoblastic T-cell line. Food Chem Toxicol. 2018 Nov;121:437-443.
3 Cellular and molecular effects of prolonged low-level sodium arsenite exposure on human hepatic HepaRG cells. Toxicol Sci. 2018 Apr 1;162(2):676-687.
4 mRNA induction and cytokine release of inflammatory mediators during in vitro exposure of human nasal respiratory epithelia to acetaldehyde. Inhal Toxicol. 2006 Dec;18(14):1083-90.
5 Di-(2-ethylhexyl)-phthalate induces apoptosis via the PPARgama/PTEN/AKT pathway in differentiated human embryonic stem cells. Food Chem Toxicol. 2019 Sep;131:110552.
6 Effect of size fractionation on the toxicity of amosite and Libby amphibole asbestos. Toxicol Sci. 2010 Dec;118(2):420-34.
7 Retinoic acid and its 4-oxo metabolites are functionally active in human skin cells in vitro. J Invest Dermatol. 2005 Jul;125(1):143-53.
8 Arzanol, a prenylated heterodimeric phloroglucinyl pyrone, inhibits eicosanoid biosynthesis and exhibits anti-inflammatory efficacy in vivo. Biochem Pharmacol. 2011 Jan 15;81(2):259-68.
9 One-year supplementation with a grape extract containing resveratrol modulates inflammatory-related microRNAs and cytokines expression in peripheral blood mononuclear cells of type 2 diabetes and hypertensive patients with coronary artery disease. Pharmacol Res. 2013 Jun;72:69-82.
10 Impact of binding site comparisons on medicinal chemistry and rational molecular design. J Med Chem. 2016 May 12;59(9):4121-51.
11 Identification of transcriptome signatures and biomarkers specific for potential developmental toxicants inhibiting human neural crest cell migration. Arch Toxicol. 2016 Jan;90(1):159-80.
12 Cyclooxygenase-1-selective inhibitors are attractive candidates for analgesics that do not cause gastric damagedesign and in vitro/in vivo evaluation of a benzamide-type cyclooxygenase-1 selective inhibitor. J Med Chem. 2008 Apr 24;51(8):2400-11.
13 The differential effects of bupivacaine and lidocaine on prostaglandin E2 release, cyclooxygenase gene expression and pain in a clinical pain model. Anesth Analg. 2008 Jan;106(1):321-7, table of contents.
14 Induction of differentiation of myeloid leukemia cells in primary culture in response to lithocholic acid acetate, a bile acid derivative, and cooperative effects with another differentiation inducer, cotylenin A. Leuk Res. 2008 Jul;32(7):1112-23.
15 Immediate up-regulation of the calcium-binding protein S100P and its involvement in the cytokinin-induced differentiation of human myeloid leukemia cells. Biochim Biophys Acta. 2005 Sep 10;1745(2):156-65.
16 Synthesis and structure-activity relationship of novel, highly potent metharyl and methcycloalkyl cyclooxygenase-2 (COX-2) selective inhibitors. J Med Chem. 2003 Dec 4;46(25):5484-504.
17 Low doses of cisplatin induce gene alterations, cell cycle arrest, and apoptosis in human promyelocytic leukemia cells. Biomark Insights. 2016 Aug 24;11:113-21.
18 Identification of mechanisms of action of bisphenol a-induced human preadipocyte differentiation by transcriptional profiling. Obesity (Silver Spring). 2014 Nov;22(11):2333-43.
19 Exploring activity cliffs in medicinal chemistry. J Med Chem. 2012 Apr 12;55(7):2932-42.
20 Dimethyl sulfoxide (DMSO) attenuates the inflammatory response in the in vitro intestinal Caco-2 cell model. Toxicol Lett. 2011 Oct 30;206(3):268-75.
21 Effect of acetylcholinesterase inhibitors donepezil and rivastigmine on the activity and expression of cyclooxygenases in a model of the inflammatory action of fluoride on macrophages obtained from THP-1 monocytes. Toxicology. 2018 Aug 1;406-407:9-20.
22 Bringing in vitro analysis closer to in vivo: studying doxorubicin toxicity and associated mechanisms in 3D human microtissues with PBPK-based dose modelling. Toxicol Lett. 2018 Sep 15;294:184-192.
23 The genomic response of a human uterine endometrial adenocarcinoma cell line to 17alpha-ethynyl estradiol. Toxicol Sci. 2009 Jan;107(1):40-55.
24 Synthesis, in vitro, and in vivo biological evaluation and molecular docking simulations of chiral alcohol and ether derivatives of the 1,5-diarylpyrrole scaffold as novel anti-inflammatory and analgesic agents. Bioorg Med Chem. 2008 Sep 1;16(17):8072-81.
25 Structural and functional basis of cyclooxygenase inhibition. J Med Chem. 2007 Apr 5;50(7):1425-41.
26 Gene expression profiling of breast cancer cells in response to gemcitabine: NF-kappaB pathway activation as a potential mechanism of resistance. Breast Cancer Res Treat. 2007 Apr;102(2):157-72.
27 Methyl-monofluorination of ibuprofen selectively increases its inhibitory activity toward cyclooxygenase-1 leading to enhanced analgesic activity and reduced gastric damage in vivo. Bioorg Med Chem Lett. 2011 Jun 15;21(12):3578-82.
28 Synthesis and structure-activity relationship of a new series of COX-2 selective inhibitors: 1,5-diarylimidazoles. J Med Chem. 2003 Jul 31;46(16):3463-75.
29 Acetaminophen selectively suppresses peripheral prostaglandin E2 release and increases COX-2 gene expression in a clinical model of acute inflammation. Pain. 2007 Jun;129(3):279-86.
30 Pharmacodynamic of cyclooxygenase inhibitors in humans. Prostaglandins Other Lipid Mediat. 2007 Jan;82(1-4):85-94.
31 Drug-metabolising enzymes are down-regulated by hypoxia in differentiated human hepatoma HepaRG cells: HIF-1alpha involvement in CYP3A4 repression. Eur J Cancer. 2009 Nov;45(16):2882-92.
32 Role of adrenoceptor-linked signaling pathways in the regulation of CYP1A1 gene expression. Biochem Pharmacol. 2005 Jan 15;69(2):277-87.
33 2,3-Diarylcyclopentenones as orally active, highly selective cyclooxygenase-2 inhibitors. J Med Chem. 1999 Apr 8;42(7):1274-81.
34 3,4-Diaryl-5-hydroxyfuranones: highly selective inhibitors of cyclooxygenase-2 with aqueous solubility. Bioorg Med Chem Lett. 2003 Mar 24;13(6):1195-8.
35 The human placental proteome is affected by maternal smoking. Reprod Toxicol. 2016 Aug;63:22-31.
36 The ERK1/2 signaling pathway regulates 11beta-hydroxysteroid dehydrogenase type 2 expression in human trophoblast cells through a transcriptional mechanism. Biol Reprod. 2013 Oct 17;89(4):92.
37 Kinetic characterization of native and cysteine 112-modified glutathione S-transferase A1-1: reassessment of nonsubstrate ligand binding. Biochemistry. 2002 Sep 10;41(36):10920-7.
38 Shotgun approach based comparative proteomic analysis of levo-tetrahydropalmatine-induced apoptosis in hepatocytes. Toxicol Lett. 2010 Apr 15;194(1-2):8-15.
39 Anti-inflammatory effects of dietary phenolic compounds in an in vitro model of inflamed human intestinal epithelium. Chem Biol Interact. 2010 Dec 5;188(3):659-67.
40 Synthetic and naturally occurring COX-2 inhibitors suppress proliferation in a human oesophageal adenocarcinoma cell line (OE33) by inducing apoptosis and cell cycle arrest. Carcinogenesis. 2004 Oct;25(10):1945-52.
41 Selective synthesis and biological evaluation of sulfate-conjugated resveratrol metabolites. J Med Chem. 2010 Jul 8;53(13):5033-43.
42 Cytokine responses of intestinal epithelial-like Caco-2 cells to non-pathogenic and opportunistic pathogenic yeasts in the presence of butyric acid. Biosci Biotechnol Biochem. 2007 Oct;71(10):2428-34.
43 Cloning, expression, and functional characterization of human cyclooxygenase-1 splicing variants: evidence for intron 1 retention. J Pharmacol Exp Ther. 2005 Dec;315(3):1298-305.
44 Bisphenol A and bisphenol S induce distinct transcriptional profiles in differentiating human primary preadipocytes. PLoS One. 2016 Sep 29;11(9):e0163318.
45 In vitro and in vivo profiling of CHF5022 and CHF5074 Two beta-amyloid1-42 lowering agents. Pharmacol Res. 2007 Apr;55(4):318-28.
46 Expanding the ChemGPS chemical space with natural products. J Nat Prod. 2005 Jul;68(7):985-91.
47 Definition of transcriptome-based indices for quantitative characterization of chemically disturbed stem cell development: introduction of the STOP-Toxukn and STOP-Toxukk tests. Arch Toxicol. 2017 Feb;91(2):839-864.
48 Cyclooxygenase-1-selective inhibitors based on the (E)-2'-des-methyl-sulindac sulfide scaffold. J Med Chem. 2012 Mar 8;55(5):2287-300.
49 Synthesis and PGE?production inhibition of s-triazine derivatives as a novel scaffold in RAW 264.7 macrophage cells. Bioorg Med Chem Lett. 2014 Dec 1;24(23):5418-22.
50 Compounds with the dioxopyrimidine cycle inhibit cholinesterases from different groups of animals. Chem Biol Interact. 2008 Sep 25;175(1-3):286-92.
51 Identification and optimisation of a novel series of pyrimidine based cyclooxygenase-2 (COX-2) inhibitorsUtilisation of a biotransformation approach. Bioorg Med Chem Lett. 2009 Aug 1;19(15):4509-14.
52 Cyclooxygenase-2 inhibitors. Synthesis and pharmacological activities of 5-methanesulfonamido-1-indanone derivatives. J Med Chem. 1995 Dec 8;38(25):4897-905.
53 3,4-Dihydroxychalcones as potent 5-lipoxygenase and cyclooxygenase inhibitors. J Med Chem. 1993 Nov 26;36(24):3904-9.
54 Synthesis and biological evaluation of the 1,5-diarylpyrazole class of cyclooxygenase-2 inhibitors: identification of 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benze nesulfonamide (SC-58635, celecoxib). J Med Chem. 1997 Apr 25;40(9):1347-65.
55 Mitochondrial involvement in schizophrenia and other functional psychoses. Neurochem Res. 1996 Sep;21(9):995-1004.
56 Keratinocyte gene expression profiles discriminate sensitizing and irritating compounds. Toxicol Sci. 2010 Sep;117(1):81-9.
57 The role of hepatocyte nuclear factor 4-alpha in perfluorooctanoic acid- and perfluorooctanesulfonic acid-induced hepatocellular dysfunction. Toxicol Appl Pharmacol. 2016 Aug 1;304:18-29.
58 Resveratrol inhibits prostaglandin formation in IL-1beta-stimulated SK-N-SH neuronal cells. J Neuroinflammation. 2009 Sep 14;6:26.
59 Human prostaglandin H synthase (hPHS)-1 and hPHS-2 in amphetamine analog bioactivation, DNA oxidation, and cytotoxicity. Toxicol Sci. 2011 Mar;120(1):154-62.

If you find any error in data or bug in web service, please kindly report it to Dr. Yin and Dr. Li.